Medpace Holdings, Inc. (MEDP) EV/FCF Ratio: 17.35x
Is Medpace Holdings, Inc.’s EV/FCF ratio high or low?
Medpace Holdings, Inc.'s EV/FCF ratio of 17.35x is 23% below its 5-year average of 22.57x, near the low end of its 5-year range (14.56x–32.89x).
As of Friday, June 19, 2026. 20.07% below its 12-month average of 21.71x.
MEDP EV/FCF Ratio Chart
MEDP Average EV/FCF Ratio Chart
MEDP Current vs Average EV/FCF Ratio Chart
MEDP EV/FCF Ratio Metrics
EV/FCF RATIO
17.35x
EV/FCF RATIO AVG TTM
21.71x
EV/FCF RATIO AVG 3Y
22.24x
EV/FCF RATIO AVG 5Y
22.57x
EV/FCF RATIO AVG 10Y
21.01x
EV/FCF RATIO AVG 15Y
N/A
EV/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-20.07%
CURRENT VS 3Y AVG
-21.98%
CURRENT VS 5Y AVG
-23.14%
CURRENT VS 10Y AVG
-17.42%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
MEDP Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $13.14B | 17.35x | 21.71x | 22.24x | 22.57x |
| Solventum Corporation (SOLV)vs › | $13.06B | N/A | 157.09x | 88.54x | 88.54x |
| Align Technology, Inc. (ALGN)vs › | $13.04B | 17.63x | 17.66x | 29.34x | 38.73x |
| DaVita Inc. (DVA)vs › | $13.34B | 17.96x | 17.77x | 17.75x | 18.16x |
| The Cooper Companies, Inc. (COO)vs › | $12.85B | 26.64x | 39.51x | 81.61x | 66.06x |
| Revvity, Inc. (RVTY)vs › | $11.16B | 27.69x | 26.79x | 265.50x | 164.11x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 66.60x | 67.40x | 78.57x | 42.55x |
| Baxter International Inc. (BAX)vs › | $10.27B | 25.09x | 65.92x | 51.53x | 47.28x |
| Hologic, Inc. (HOLX)vs › | $16.97B | 17.53x | 16.94x | 18.67x | 15.16x |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.02B | 13.22x | 16.05x | 23.18x | 24.85x |
Cash Flow Valuation Comparison
EV/FCF
17.4x
P/FCF
18.1x
FCF Yield
5.54%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
Medpace Holdings, Inc. EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medpace Holdings, Inc. EV/FCF Ratio FAQ
- What is the EV/FCF ratio for Medpace Holdings, Inc. (MEDP)?
- The EV/FCF ratio for MEDP stock is 17.35x.
- Is Medpace Holdings, Inc.'s EV/FCF ratio high or low?
- Medpace Holdings, Inc.'s EV/FCF ratio of 17.35x is 23% below its 5-year average of 22.57x, near the low end of its 5-year range (14.56x–32.89x).
- What is the TTM average EV/FCF ratio for Medpace Holdings, Inc. (MEDP)?
- The TTM average EV/FCF ratio for MEDP stock is 21.71x.
- What is the 3Y average EV/FCF ratio for Medpace Holdings, Inc. (MEDP)?
- The 3Y average EV/FCF ratio for MEDP stock is 22.24x.
- What is the 5Y average EV/FCF ratio for Medpace Holdings, Inc. (MEDP)?
- The 5Y average EV/FCF ratio for MEDP stock is 22.57x.
- What is the 10Y average EV/FCF ratio for Medpace Holdings, Inc. (MEDP)?
- The 10Y average EV/FCF ratio for MEDP stock is 21.01x.
Medpace Holdings, Inc. EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-18 | 17.35x |
| 2026-06-17 | 17.22x |
| 2026-06-16 | 17.40x |
| 2026-06-15 | 17.63x |
| 2026-06-12 | 17.63x |
| 2026-06-11 | 17.93x |
| 2026-06-10 | 17.56x |
| 2026-06-09 | 17.60x |
| 2026-06-08 | 17.26x |
| 2026-06-05 | 17.11x |
| 2026-06-04 | 17.29x |
| 2026-06-03 | 16.98x |
| 2026-06-02 | 16.77x |
| 2026-06-01 | 17.00x |
| 2026-05-29 | 16.83x |
| 2026-05-28 | 16.87x |
| 2026-05-27 | 16.08x |
| 2026-05-26 | 16.13x |
| 2026-05-22 | 16.27x |
| 2026-05-21 | 16.16x |
| 2026-05-20 | 15.84x |
| 2026-05-19 | 15.76x |
| 2026-05-18 | 15.79x |
| 2026-05-15 | 15.58x |
| 2026-05-14 | 15.73x |
| 2026-05-13 | 15.92x |
| 2026-05-12 | 15.76x |
| 2026-05-11 | 15.66x |
| 2026-05-08 | 15.92x |
| 2026-05-07 | 16.11x |
| 2026-05-06 | 16.03x |
| 2026-05-05 | 16.17x |
| 2026-05-04 | 15.65x |
| 2026-05-01 | 15.67x |
| 2026-04-30 | 15.71x |
| 2026-04-29 | 15.52x |
| 2026-04-28 | 15.36x |
| 2026-04-27 | 15.82x |
| 2026-04-24 | 15.40x |
| 2026-04-23 | 14.72x |
| 2026-04-22 | 20.43x |
| 2026-04-21 | 20.70x |
| 2026-04-20 | 21.25x |
| 2026-04-17 | 20.93x |
| 2026-04-16 | 20.73x |
| 2026-04-15 | 20.84x |
| 2026-04-14 | 20.90x |
| 2026-04-13 | 20.14x |
| 2026-04-10 | 19.82x |
| 2026-04-09 | 20.15x |
| 2026-04-08 | 20.93x |
| 2026-04-07 | 20.44x |
| 2026-04-06 | 19.92x |
| 2026-04-02 | 20.02x |
| 2026-04-01 | 19.66x |
| 2026-03-31 | 19.28x |
| 2026-03-30 | 18.46x |
| 2026-03-27 | 18.09x |
| 2026-03-26 | 18.72x |
| 2026-03-25 | 18.73x |
| 2026-03-24 | 18.48x |
| 2026-03-23 | 18.33x |
| 2026-03-20 | 18.15x |
| 2026-03-19 | 18.49x |
| 2026-03-18 | 18.24x |
| 2026-03-17 | 18.25x |
| 2026-03-16 | 18.19x |
| 2026-03-13 | 18.06x |
| 2026-03-12 | 17.79x |
| 2026-03-11 | 19.18x |
| 2026-03-10 | 18.73x |
| 2026-03-09 | 19.21x |
| 2026-03-06 | 18.89x |
| 2026-03-05 | 18.84x |
| 2026-03-04 | 18.69x |
| 2026-03-03 | 18.67x |
| 2026-03-02 | 18.35x |
| 2026-02-27 | 18.12x |
| 2026-02-26 | 17.92x |
| 2026-02-25 | 17.56x |
| 2026-02-24 | 17.72x |
| 2026-02-23 | 17.84x |
| 2026-02-20 | 18.20x |
| 2026-02-19 | 17.90x |
| 2026-02-18 | 17.89x |
| 2026-02-17 | 17.15x |
| 2026-02-13 | 17.15x |
| 2026-02-12 | 16.66x |
| 2026-02-11 | 16.98x |
| 2026-02-10 | 17.88x |
| 2026-02-09 | 22.19x |
| 2026-02-06 | 22.69x |
| 2026-02-05 | 22.65x |
| 2026-02-04 | 23.51x |
| 2026-02-03 | 23.81x |
| 2026-02-02 | 24.64x |
| 2026-01-30 | 24.39x |
| 2026-01-29 | 24.84x |
| 2026-01-28 | 25.05x |
| 2026-01-27 | 25.23x |
| 2026-01-26 | 25.22x |
| 2026-01-23 | 24.63x |
| 2026-01-22 | 25.40x |
| 2026-01-21 | 26.00x |
| 2026-01-20 | 25.24x |
| 2026-01-16 | 25.59x |
| 2026-01-15 | 25.90x |
| 2026-01-14 | 25.83x |
| 2026-01-13 | 25.49x |
| 2026-01-12 | 25.10x |
| 2026-01-09 | 24.92x |
| 2026-01-08 | 25.14x |
| 2026-01-07 | 25.69x |
| 2026-01-06 | 25.51x |
| 2026-01-05 | 24.58x |
| 2026-01-02 | 23.91x |
| 2025-12-31 | 23.52x |
| 2025-12-30 | 23.82x |
| 2025-12-29 | 23.87x |
| 2025-12-26 | 23.76x |
| 2025-12-24 | 23.95x |
| 2025-12-23 | 23.86x |
| 2025-12-22 | 23.93x |
| 2025-12-19 | 23.80x |
| 2025-12-18 | 23.45x |
| 2025-12-17 | 23.32x |
| 2025-12-16 | 23.39x |
| 2025-12-15 | 23.41x |
| 2025-12-12 | 23.36x |
| 2025-12-11 | 23.71x |
| 2025-12-10 | 23.48x |
| 2025-12-09 | 22.77x |
| 2025-12-08 | 22.99x |
| 2025-12-05 | 22.94x |
| 2025-12-04 | 22.80x |
| 2025-12-03 | 24.14x |
| 2025-12-02 | 24.45x |
| 2025-12-01 | 24.63x |
| 2025-11-28 | 24.82x |
| 2025-11-26 | 25.41x |
| 2025-11-25 | 25.63x |
| 2025-11-24 | 25.92x |
| 2025-11-21 | 24.79x |
| 2025-11-20 | 24.55x |
| 2025-11-19 | 24.80x |
| 2025-11-18 | 24.72x |
| 2025-11-17 | 24.53x |
| 2025-11-14 | 24.72x |
| 2025-11-13 | 24.77x |
| 2025-11-12 | 25.03x |
| 2025-11-11 | 25.25x |
| 2025-11-10 | 25.15x |
| 2025-11-07 | 24.68x |
| 2025-11-06 | 24.80x |
| 2025-11-05 | 25.08x |
| 2025-11-04 | 24.90x |
| 2025-11-03 | 24.88x |
| 2025-10-31 | 24.50x |
| 2025-10-30 | 24.31x |
| 2025-10-29 | 24.48x |
| 2025-10-28 | 24.31x |
| 2025-10-27 | 24.99x |
| 2025-10-24 | 25.35x |
| 2025-10-23 | 24.99x |
| 2025-10-22 | 28.62x |
| 2025-10-21 | 28.57x |
| 2025-10-20 | 28.50x |
| 2025-10-17 | 27.65x |
| 2025-10-16 | 27.29x |
| 2025-10-15 | 26.94x |
| 2025-10-14 | 27.07x |
| 2025-10-13 | 27.62x |
| 2025-10-10 | 26.25x |
| 2025-10-09 | 27.16x |
| 2025-10-08 | 27.80x |
| 2025-10-07 | 27.85x |
| 2025-10-06 | 27.77x |
| 2025-10-03 | 27.88x |
| 2025-10-02 | 28.07x |
| 2025-10-01 | 28.47x |
| 2025-09-30 | 26.93x |
| 2025-09-29 | 26.23x |
| 2025-09-26 | 26.02x |
| 2025-09-25 | 25.56x |
| 2025-09-24 | 26.05x |
| 2025-09-23 | 25.99x |
| 2025-09-22 | 26.09x |
| 2025-09-19 | 26.12x |
| 2025-09-18 | 26.29x |
| 2025-09-17 | 26.08x |
| 2025-09-16 | 25.71x |
| 2025-09-15 | 26.00x |
| 2025-09-12 | 25.70x |
| 2025-09-11 | 26.07x |
| 2025-09-10 | 24.98x |
| 2025-09-09 | 25.44x |
| 2025-09-08 | 25.78x |
| 2025-09-05 | 25.51x |
| 2025-09-04 | 25.27x |
| 2025-09-03 | 25.21x |
| 2025-09-02 | 24.80x |
| 2025-08-29 | 24.92x |
| 2025-08-28 | 24.78x |
| 2025-08-27 | 24.81x |
| 2025-08-26 | 24.59x |
| 2025-08-25 | 24.46x |
| 2025-08-22 | 24.30x |
| 2025-08-21 | 23.76x |
| 2025-08-20 | 24.41x |
| 2025-08-19 | 24.22x |
| 2025-08-18 | 24.26x |
| 2025-08-15 | 24.00x |
| 2025-08-14 | 24.04x |
| 2025-08-13 | 24.53x |
| 2025-08-12 | 24.07x |
| 2025-08-11 | 23.58x |
| 2025-08-08 | 22.78x |
| 2025-08-07 | 22.49x |
| 2025-08-06 | 22.57x |
| 2025-08-05 | 22.88x |
| 2025-08-04 | 22.68x |
| 2025-08-01 | 22.19x |
| 2025-07-31 | 22.40x |
| 2025-07-30 | 22.95x |
| 2025-07-29 | 23.48x |
| 2025-07-28 | 23.75x |
| 2025-07-25 | 23.46x |
| 2025-07-24 | 23.89x |
| 2025-07-23 | 22.93x |
| 2025-07-22 | 25.03x |
| 2025-07-21 | 17.23x |
| 2025-07-18 | 17.40x |
| 2025-07-17 | 17.82x |
| 2025-07-16 | 17.57x |
| 2025-07-15 | 17.45x |
| 2025-07-14 | 17.89x |
| 2025-07-11 | 18.07x |
| 2025-07-10 | 18.35x |
| 2025-07-09 | 17.93x |
| 2025-07-08 | 18.02x |
| 2025-07-07 | 17.81x |
| 2025-07-03 | 17.96x |
| 2025-07-02 | 18.22x |
| 2025-07-01 | 17.93x |
| 2025-06-30 | 17.52x |
| 2025-06-27 | 17.34x |
| 2025-06-26 | 17.11x |
| 2025-06-25 | 17.36x |
| 2025-06-24 | 17.60x |
| 2025-06-23 | 17.22x |
| 2025-06-20 | 17.26x |
| 2025-06-18 | 16.87x |
| 2025-06-17 | 16.60x |
| 2025-06-16 | 16.78x |
| 2025-06-13 | 16.62x |
| 2025-06-12 | 16.95x |
| 2025-06-11 | 16.85x |
| 2025-06-10 | 17.06x |
| 2025-06-09 | 16.62x |
| 2025-06-06 | 16.52x |
Showing the most recent 260 of 2,477 data points. The chart above shows the full history.
Related Metrics
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle